Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 154

Results For "Chief"

2169 News Found

Capnopharm to acquire operational assets of Capnomed
News | July 10, 2022

Capnopharm to acquire operational assets of Capnomed

Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.


CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine
News | July 06, 2022

CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine

CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.


Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
News | July 06, 2022

Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine

Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells


ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India
People | July 05, 2022

ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India

Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.


Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
Healthcare | July 05, 2022

Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Medicines, including insulin, to be available in 40 lower-income countries


OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212
Drug Approval | July 04, 2022

OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212

The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.


Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Clinical Trials | July 04, 2022

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection


Pfizer submits new drug application to the U.S. FDA for Paxlovid
Drug Approval | July 03, 2022

Pfizer submits new drug application to the U.S. FDA for Paxlovid

Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk